Please assess the completion status of the following clinical trial:

Trial Title: 12-h and 2-h Urokinase Regimes of Pulmonary Thromboembolism in China

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* PTE confirmed either by a high probability ventilation-perfusion lung scanning (V/Q scan) or by CTPA.~* massive PTE patients with haemodynamic instability and/or cardiogenic shock~* Anatomic obstruction more than 2 lobes on CTPA and/or defect more than 7 segments on V/Q scan with evidence of right ventricular dysfunction (RVD) and pulmonary hypertension on echocardiography~* Symptoms within 15 days~* Written informed consent was obtained from all the patients before randomization~Exclusion Criteria:~* Received parenteral heparin for more than 72 hours~* Known allergic to urokinase~* Thrombolytic contraindications such as:~  1. active bleeding or spontaneous intracranial hemorrhage;~ 2. major surgery, organ biopsy or recent puncture of a non-compressible vessel less than 10 days;~ 3. cerebral arterial thrombosis within 2 months;~ 4. gastro-intestinal bleeding within 10 days;~ 5. major trauma within the past 15 days;~ 6. neurosurgery or ophthalmologic operation with 30 days;~ 7. uncontrolled hypertension (systolic blood pressure \> 180 mmHg and/or diastolic blood pressure \> 110 mmHg);~ 8. recent external cardiac resuscitation manoeuvres;~ 9. platelet count \< 100 000/mm3 at admission;~ 10. pregnancy, puerperium or lactation with 2 weeks;~ 11. infectious pericarditis or endocarditis;~ 12. severe hepatic and kidney dysfunction;~ 13. hemorrhagic retinopathy due to diabetes;~ 14. a known bleeding disorder.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Group 1 (Type: ACTIVE_COMPARATOR): UK-12h group
- Group 2 (Type: EXPERIMENTAL): UK-2h group

Based on this trial design, predict the completion outcome and termination type (if applicable).